The objective of this study is to measure economic burden of Multiple Sclerosis (MS) from a new point of view that includes consequences of disability on Quality Of Life (QOL), social participation and capabilities of patients and caregivers. To the investigators' knowledge, there is currently no data including intangible costs related to caregivers and calculating the overall economic cost of Multiple Sclerosis, particularly, in France.
The goal of this study is to evaluate prospectively the economic burden of Multiple Sclerosis (MS) in France by calculating direct costs (medical and non-medical) and indirect costs and by estimating consequences of MS on utility (QALY) of patients and caregivers in a societal perspective.
Study Type
OBSERVATIONAL
Enrollment
233
Annual average total health care cost of the Multiple Sclerosis by patient
Global cost of Multiple Sclerosis considering direct medical and non-medical costs as well as the indirect and intangible costs associated to the patient-caregiver
Time frame: 1 year
Score of social participation
Correlation between the score of social participation and health care costs of the disease will be determined
Time frame: 1 year
Validity of life quality measurement EQ-5D
The EQ-5D index is a generic measure of health status that provides a simple descriptive profile and a single index value that can be used in the clinical and economic evaluation of health care
Time frame: 1 year
Utilities measured by the Short Form-6D (SF-6D)
The SF-6D is a utility index based on a descriptive system composed of 11 items from six dimensions of the SF-36: physical functioning, role limitations, social functioning, pain, mental functioning and vitality.
Time frame: 1 year
QALY
Health related quality in life will be measured as Quality adjusted life years (QALY)
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.